[Study of clinical bacteriological efficacy in a cefmenoxime ototopical solution]

Area of Science:

• Otolaryngology
• Infectious Diseases
• Microbiology

Background:

• Purulent otitis media and acute diffuse external otitis are common ear infections.
• Identifying causative bacteria and their antibiotic susceptibility is crucial for effective treatment.
• Cefmenoxime (CMX) is a cephalosporin antibiotic with potential ototopical applications.

Purpose of the Study:

• To evaluate the efficacy and antibacterial activity of a 1% cefmenoxime (CMX) ototopical solution.
• To assess CMX's minimum inhibitory concentrations (MIC) against bacteria isolated from ear infections.
• To compare CMX's activity with reference antibiotics: cefazolin (CEZ), chloramphenicol (CP), and fradiomycin (FRM).

Main Methods:

• Open study and double-blind trials involving 518 patients with purulent otitis media and acute diffuse external otitis.
• Bacterial isolation and identification from ear exudates.
• Determination of MIC values for CMX, CEZ, CP, and FRM against isolated bacterial strains.

Main Results:

• The most frequently detected bacteria were Staphylococcus aureus (49.1%), Pseudomonas aeruginosa (21.3%), and Staphylococcus epidermidis (13.6%).
• CMX demonstrated favorable antibacterial action against S. aureus, P. aeruginosa, Streptococcus spp., and anaerobic bacteria.
• CMX showed stable and strong activity against certain Gram-negative rods, including Proteus spp. (indole positive), while less effective against P. cepacia, P. putida, and A. xylosoxidans.

Conclusions:

• The 1% cefmenoxime ototopical solution exhibits significant antibacterial activity against key pathogens causing ear infections.
• CMX demonstrates a favorable MIC profile against common bacteria, including those resistant to other antibiotics.
• Cefmenoxime is a promising therapeutic agent for treating bacterial otitis media and external otitis.